Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


123456789>>>
1718 Items
Title  Creator  Group name  Publishing year 
Tumor-intrinsic chemosensitivity assessed by KELIM and prognosis by BRCA status in patients with advanced ovarian carcinomas Becker et al. EquipeCTCS 2025-01-06
Surface modification of extracellular vesicles with polyoxazolines to enhance their plasma stability and tumor accumulation Simon et al. EquipeJPP 2025-02
Replication poison treated BRCA1-deficient breast cancers are prone to MRE11 over-resection resulting in single strand DNA accumulation and mitotic catastrophe. Tabet et al. EquipeCTCS 2025
Pushing the boundaries of radiotherapy-immunotherapy combinations: highlights from the 7th immunorad conference Laurent et al. EquipeJPP 2025-12
MHC-I-driven anti-tumor immunity counterbalances low absorbed doses of targeted radionuclide therapy J. Constanzo et al. EquipeJPP 2025 (in press)
E4F1 coordinates pyruvate metabolism and the activity of the elongator complex to ensure translation fidelity during brain development Di Michele et al. EquipeCTCS 2025-01-02
Discovery of a pan anti-SARS-CoV-2 monoclonal antibody with highly efficient infected cell killing capacity for novel immunotherapeutic approaches Abba Moussa et al. EquipePM 2025-12
[Preventing the risks of interaction between cancer treatments and complementary care strategies] Ninot et al. EquipeAD 2024-11-15
[Drosophila as a model to study cancer biology] Falconi et al. EquipeAD 2024-09
[Contribution of intraperitoneal chemotherapy in the treatment of colorectal peritoneal carcinoma. HIPEC, PIPAC, state of the art and future directions] Quénet et al. EquipePM 2024-03
[68Ga]Ga-FAPI-46 synthesis on a GAIA® module system: Thorough study of the automated radiolabeling reaction conditions Rubira et al. EquipeJPP 2024-04
Why Is Wnt/?-Catenin Not Yet Targeted in Routine Cancer Care? de Pellegars-Malhortie et al. EquipeMY 2024-07-16
What Does N2 Lymph Node Involvement Mean for Patients with Non-Small Cell Lung Cancer (NSCLC)?-A Review of Implications for Diagnosis and Treatment Linares Díaz et al. EquipeMY 2024-07-26
Vitamin C enhances co-localization of novel TET1 nuclear bodies with both Cajal and PML bodies in colorectal cancer cells El Osmani et al. EquipeMY 2024-12
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer Bardia et al. EquipeCTCS 2024-12-05
Towards Optimal Automated 68Ga-Radiolabeling Conditions of the DOTA-Bisphosphonate BPAMD Without Pre-Purification of the Generator Eluate Souche et al. EquipeJPP 2024-11-20
The Translation of Dosimetry into Clinical Practice: What It Takes to Make Dosimetry a Mandatory Part of Clinical Practice Bardiès et al. EquipeJPP 2024-12-03
The Hippo pathway terminal effector TAZ/WWTR1 mediates oxaliplatin sensitivity in p53 proficient colon cancer cells Slaninová et al. EquipeAD 2024-05-14
Symposium on molecular radiotherapy dosimetry: The first of a series? Bardiès et al. EquipeJPP 2024-04
Serotonergic underpinnings of obsessive-compulsive disorder: A systematic review and meta-analysis of neuroimaging findings Pastre et al. EquipeJPP 2024-11-07
Robotic posterior pelvic exenteration for locally advanced rectal cancer-A video vignette Colombo et al. EquipeCTCS 2024-10
Regorafenib plus FOLFIRINOX as first-line treatment for patients with RAS-mutant metastatic colorectal cancer (FOLFIRINOX-R trial): a dose-escalation study Adenis et al. EquipeMY 2024-09
Quality Assurance Considerations in Radiopharmaceutical Therapy Dosimetry Using PLANETDose: An International Atomic Energy Agency Study Kayal et al. EquipeJPP 2024-01-02
Prognostic value of the tumor-to-liver density ratio in patients with metastatic colorectal cancer treated with bevacizumab-based chemotherapy. A post-hoc study of the STIC-AVASTIN trial Mazard et al. EquipeMY 2024-06-17
Prognostic value of tertiary lymphoid structures in triple-negative breast cancer: integrated analysis with the tumor microenvironment and clinicopathological features Boissière-Michot et al. EquipeCTCS 2024
123456789>>>
1718 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés